文献速递乳腺癌放疗

基于FDG/PET-CT的乳腺癌患者淋巴结图谱

FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-08-14

本研究纳入235例患者共580个FDG/PET-CT阳性的区域淋巴结转移灶,按原发或复发及有无远处转移分为4组,构建三维淋巴结图谱并评估RTOG与ESTRO临床靶区勾画指南的覆盖情况。结果显示多数淋巴结位于I水平,RTOG与ESTRO指南对原发乳腺癌淋巴结体积覆盖分别为69.8%±35.5%与69.1%±36.3%,对复发乳腺癌分别为57.6%±38.9%与51.1%±39.1%。

要点

  • 580个FDG/PET-CT阳性淋巴结中,I水平最多(316个,54.5%),其次为锁骨上区(80个,13.8%)。
  • RTOG与ESTRO指南覆盖的原发乳腺癌淋巴结体积分别为69.8%±35.5%与69.1%±36.3%。
  • 复发乳腺癌中内乳区和锁骨上区受累较原发乳腺癌更常见,锁骨上区、内乳区和II水平几何偏差最大。

核心结论

  • 所构建的淋巴结图谱展示了不同临床情况下淋巴结转移的发生位置,并呈现了淋巴结转移的高风险区域即「热点」。

研究设计与样本

  • 回顾性分析235例患者共580个FDG/PET-CT阳性的区域淋巴结转移灶,按原发或复发乳腺癌及有无远处转移分为4组。
  • 将所有影像数据导入计划系统并手动勾画每个淋巴结,以「标准解剖」患者为模板进行刚性及非刚性配准,构建包含全部已识别淋巴结转移灶的三维图谱。
  • 按RTOG与ESTRO指南勾画腋窝、内乳、锁骨上淋巴结区域并评估其覆盖情况。

主要发现

  • 淋巴结平均体积为1.7±2.6 cm³,平均直径为1.3±0.7 cm。
  • 淋巴结分布为I水平316个(54.5%)、锁骨上区80个(13.8%)、II水平57个(9.8%)、III水平58个(10.0%)、内乳区55个(9.5%)。
  • RTOG(ESTRO)指南覆盖的淋巴结体积在原发乳腺癌为69.8%±35.5%(69.1%±36.3%),在复发乳腺癌为57.6%±38.9%(51.1%±39.1%)。
  • 复发乳腺癌较原发乳腺癌的内乳区和锁骨上区受累更常见。
  • 有远处转移与无远处转移患者中,淋巴结转移出现在RTOG和ESTRO边界之外的情况相似。

关键数值与推荐

  • RTOG指南覆盖的原发乳腺癌淋巴结体积为69.8%±35.5%,ESTRO指南为69.1%±36.3%。
  • RTOG指南覆盖的复发乳腺癌淋巴结体积为57.6%±38.9%,ESTRO指南为51.1%±39.1%。
  • 淋巴结平均体积1.7±2.6 cm³,平均直径1.3±0.7 cm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to localize locoregional lymph node metastases using positron emission tomography with fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) data sets in a large cohort of patients and to evaluate the existing Radiation Therapy Oncology Group (RTOG) clinical target volume (CTV) and the European Society for Radiation Therapy & Oncology (ESTRO) CTV contouring guidelines. METHODS AND MATERIALS: A total of 235 patients with 580 FDG/PET-CT positive locoregional lymph node metastases were included in our analysis. The patients were divided into 4 groups according to their course of disease (primary vs recurrent breast cancer) and the presence or absence of distant metastasis at the time of the FDG-PET/CT staging (distant metastasis vs no distant metastasis). All imaging data were imported into the planning system, and each lymph node was manually contoured. A patient with "standard anatomy" was chosen as a template, and all contoured structures were registered rigidly and nonrigidly to this patient. A comprehensive 3-dimensional atlas was created, including all identified lymph node metastases. The incidences of lymph node metastases were analyzed and are presented with color coding in the atlas. Lymph node levels (axillary, internal mammary, supraclavicular) were contoured according to RTOG and ESTRO guidelines and evaluated. RESULTS: The mean volume of the lymph nodes was 1.7 ± 2.6 cm3 with an average diameter of 1.3 ± 0.7 cm. Most lymph nodes were in level I (n = 316; 54.5%) followed by the supraclavicular region (n = 80; 13.8%), level II (n = 57; 9.8%), level III (n = 58; 10.0%), and the internal mammary region (n = 55; 9.5%). The covered lymph node volume was 69.8% ± 35.5% (69.1% ± 36.3%) for primary breast cancer and 57.6% ± 38.9% (51.1% ± 39.1%) for recurrent breast cancer using the RTOG (ESTRO) guidelines. The internal mammary region and supraclavicular region were affected more often in recurrent breast cancer compared with primary breast cancer. The occurrence of lymph node metastases outside the RTOG and ESTRO margins in patients with and without distant metastases was similar. The largest geometric deviations between RTOG/ESTRO CTV contours and lymph node occurrence were measured in the supraclavicular region, the internal mammary region, and level II. CONCLUSIONS: The provided lymph node atlas illustrates where lymph node metastases occur in different clinical situations and presents areas at high risk (ie "hot spots" of lymph node metastases).

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Borm KJ, Voppichler J, Düsberg M, et al. FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients. Int J Radiat Oncol Biol Phys. 2018. PMID: 30118822. doi:10.1016/j.ijrobp.2018.07.2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。